Here are relevant reports on : nicotine-replacement-therapy-market
-
Elastomeric Pumps Market by Product (Continuous Rate, Variable Rate), Treatment (Chemotherapy, Antibiotic, Iron Chelation Therapy), Administration Route (Intravenous, Subcutaneous), End User (Hospital, Ambulatory Surgery Center) - Global Forecast to 2022
The global elastomeric pumps market is expected to reach USD 592.0 Million by 2022 from USD 432.1 Million in 2017, growing at a CAGR of 6.5% from 2017 to 2022. Increasing number of surgeries, wide usage in treatment, rising incidence of chronic diseases, and increasing adoption for disposable infusion pumps, are some of the major driving factors driving the growth of the global elastomeric pumps market. However, the high cost of treatment and challenges in reimbursement are hindering the growth of this market to a certain extent.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific Healthcare Market Outlook – [By Health Indicators (Life Expectancy, Mortality), Disease Burden (Epidemiology, Average Cost Of Therapy), Health System (Infrastructure, Expenditure), Regulatory Landscape] - Analysis & Forecast To 2020
The APAC region showcases diverse healthcare challenges across various countries. These range from improving healthcare access in developing countries of Vietnam to tackling rising diabetes, cancer, and cardiovascular diseases in well developed nations of Japan and Pacific countries. In addition, regions of China and India that lie in between developing and well developed countries are facing increase in diseases burden, problems of poverty, limited access to high quality treatment, and slow increase in disposable income. The APAC Healthcare Market Outlook examines the health indicators and healthcare system across India, China, Japan, Singapore, Indonesia, Thailand, Malaysia, Vietnam, Australia, and New Zealand. The APAC Healthcare Market Outlook is segmented into five broad categories: health status, healthcare system assessment, healthcare regulatory landscape, medical devices infrastructure assessment, hospital chain assessment in top 10 hospitals.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Inflammatory, Autoimmune, Cardiovascular) & Region - Global Forecast to 2028
The global stem cell therapy market, valued at US$259 million in 2022, stood at US$286 million in 2023 and is projected to advance at a resilient CAGR of 16.5% from 2023 to 2028, culminating in a forecasted valuation of US$615 million by the end of the period. Market growth is driven mainly by factors such as rise in funding for stem cell research, upsurge in the number of cell therapy production facilities that have GMP certification, and increased in the number of clinical trials associated with stem cell therapies.
- Published: December 2023
- Price: $ 4950
- TOC Available:
-
Neuroblastoma Cancer Market by Diagnostics (MIBG Scan, Imaging, Urine Analysis, Biopsy), Treatment (Surgery, Chemotherapy, Radiation therapy, Stem Cell Transplant, Immunotherapy), Staging, Pipeline, Regulatory, Reimbursement - Global Forecast to 2021
Neuroblastoma is a rare extracranial solid tumor cancer that develops from immature nerve cells found in several areas of the body. It is the most common extracranial solid tumor in childhood.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Intraoperative Radiation Therapy Market Size, Share & Trends by Technology (Electron IORT, Brachytherapy), Products & Services (Accelerators, Treatment Planning system, Applicators, Afterloaders, Accessories), Application (Breast, Brain, Lung Cancer) & Region - Global Forecast to 2025
The global intraoperative radiation therapy market in terms of revenue was estimated to be worth USD 48 million in 2020 and is poised to reach USD 66 million by 2025, growing at a CAGR of 6.4% from 2020 to 2025. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
- Published: February 2021
- Price: $ 4950
- TOC Available:
-
Ultrasonic Tissue Ablation System Market by Type (HIFU Ablators, MRGFUS Ablators, Ultrasonic Surgical Ablation, Shock Wave Therapy Systems), Application (Cardiac Diseases, Cancer, Pain Management) & End User (Hospitals, Clinics) - Global Forecast to 2023
The global ultrasonic tissue ablation system market is expected to reach USD 1,449.2 million by 2023 from USD 840.9 million in 2018, growing at a CAGR of 11.5%. Increasing prevalence of chronic diseases; rising adoption of minimally invasive surgeries; ongoing technological advancements in the field of ablation devices, growing awareness about benefits of ablation procedures over conventional therapeutic and surgical procedures, and rising number of hospitals and surgical centers are some of the major factors driving the growth of the global suture anchor market. These driving factors consequence to the rapid adoption of these new devices, thus propelling the market growth.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) - Global Forecast to 2035
The global radioligand therapy market, valued at US$2.36 billion in 2024, stood at US$3.15 billion in 2025 and is projected to advance at a resilient CAGR of 13.2% from 2025 to 2035, culminating in a forecasted valuation of US$10.91 billion by the end of the period. The growth of this market is primarily attributed to factors such as increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, and the rising adoption of PSMA and SSTR PET imaging for patient selection.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Veterinary Monoclonal Antibodies Market by Animal Type (Canine, Feline, Swine), Product (Cytopoint, Librela, Solensia), Therapy Area (Dermatology, Infectious, Osteoarthritis, Pain, Oncology, Others), Route of Administration - Global Forecast to 2030
The global veterinary monoclonal antibodies market, valued at US$1.52 billion in 2024, stood at US$1.70 billion in 2025 and is projected to advance at a resilient CAGR of 12.4% from 2025 to 2030, culminating in a forecasted valuation of US$3.06 billion by the end of the period. Opportunities in the market involve expanding therapeutic uses beyond dermatology and osteoarthritis, as well as developing new administration routes for monoclonal antibodies.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Vitamin D Therapy Market by Route of administration (Oral, Parenteral), Age Group (Children, Adult, Senior Adult), Purchase Pattern (OTC, Prescription), Application (Osteoporosis, Rickets, Autoimmune Disorder, Skin Diseases) - Global Forecast to 2024
The vitamin D therapy market is projected to reach USD 3.3 billion by 2024 from USD 1.9 billion in 2019, at a CAGR of 11.6% during the forecast period. Growth in this market is largely driven by the growing awareness about vitamin D deficiency and the presence of a large target patient population. On the other hand, the fortification of foods is likely to challenge the growth of this market. Some of the major players in this market include Abbott (US), Sanofi (France), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Merck & Co., Inc. (US), Torrent Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Alkem Laboratories (India), Sun Pharmaceutical Industries Ltd. (India), and Cadila Healthcare Ltd. (India).
- Published: April 2019
- Price: $ 4950
- TOC Available:
-
Biologics Safety Testing Market by Product & Service (Consumables, Instrument, Services), Test Type (Mycoplasma, Sterility, Endotoxin, Bioburden, Virus Safety), Application (Vaccines, mAbs, Cell & Gene Therapy, Blood Products) - Global Forecast to 2029
The global biologics safety testing market, valued at US$3.9 billion in 2023, stood at US$4.2 billion in 2024 and is projected to advance at a resilient CAGR of 11.1% from 2024 to 2029, culminating in a forecasted valuation of US$7.2 billion by the end of the period. Growth of the market can be attributed to factors such as the rising need for novel biotherapeutics and increasing focus on advancement of biopharmaceutical industry.
- Published: May 2024
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
